{"abstract_id": 3392, "endpoint_id": 168, "truth": 1, "pred": 1, "blended_prob": 0.879448275862069, "llm_prob": 0.96, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The single\u2011arm phase\u202fII study enrolled 24 patients and reported an overall response rate of 75%, exceeding the pre\u2011specified threshold of 60% for further development. The sample size is modest but sufficient for the primary endpoint, and the ORR is clearly defined and measured per standard criteria, supporting a robust positive outcome.", "citations": [{"title": "Phase II trial of cisplatin\u2011RT with pembrolizumab in vulvar cancer (NCT04430699)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04430699"}]}
{"abstract_id": 2892, "endpoint_id": 125, "truth": 1, "pred": 1, "blended_prob": 0.77, "llm_prob": 0.7, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Safety conclusion not directly supported by retrieved external evidence"], "green": []}, "rationale": "The trial reports that no new safety signals emerged after 9 years of follow\u2011up, satisfying the decision rule. The large randomized sample (n=1096) and long follow\u2011up strengthen confidence, though external citations confirming safety are lacking.", "citations": []}
{"abstract_id": 1698, "endpoint_id": 100, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Endpoint outcome not directly supported by retrieved external evidence"], "green": []}, "rationale": "The trial reports an ICR-assessed ORR of 20.0% in Group B with a one-sided p\u2011value of 0.0362, which is below the 0.05 threshold required to reject the null hypothesis of \u22645% response, indicating the primary endpoint is met despite the small sample size (n=15).", "citations": []}
{"abstract_id": 4719, "endpoint_id": 247, "truth": 1, "pred": 1, "blended_prob": 0.75, "llm_prob": 0.85, "base_prob": 0.6, "base_note": "Base rate from unknown / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["Biomarker tier GREEN"]}, "rationale": "The phase II randomized trial with 95 patients evaluated immunological biomarkers (Th7R and Th2) and demonstrated statistically significant associations with progression\u2011free and overall survival for osimertinib, fulfilling the exploratory co\u2011primary endpoint of identifying biomarkers predictive of treatment outcomes.", "citations": []}
{"abstract_id": 3679, "endpoint_id": 190, "truth": 1, "pred": 1, "blended_prob": 0.748, "llm_prob": 0.78, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Small sample size and borderline p\u2011value for irAEs"], "green": []}, "rationale": "The randomized phase\u202f2 trial (n=150) reported immune\u2011related adverse events in 5/75 (6.7%) patients receiving toripalimab versus 0/75 in the control arm, with a p\u2011value of 0.058, which does not meet the predefined significance threshold (p\u202f\u2265\u202f0.05). Thus, the decision rule indicates no significant difference in harm.", "citations": [{"title": "NCT05340270 \u2013 Toripalimab plus induction chemotherapy versus chemotherapy alone in LANPC", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05340270"}]}
{"abstract_id": 1825, "endpoint_id": 271, "truth": 1, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target wee1 kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to robustly confirm the endpoint outcome"], "green": []}, "rationale": "The trial description states that no major changes in etoposide exposure were observed across Debio 0123 dose levels, suggesting the decision rule is met; however, the lack of corroborating data in the retrieved evidence reduces confidence.", "citations": []}
{"abstract_id": 1288, "endpoint_id": 76, "truth": 1, "pred": 1, "blended_prob": 0.7095, "llm_prob": 0.62, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target ep4 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for safety outcome not directly cited from retrieved sources"], "green": []}, "rationale": "The trial reports that no treatment\u2011related serious or grade\u202f>\u202f3 adverse events occurred among 27 patients, satisfying the predefined safety decision rule, though the supporting statement is not present in the retrieved evidence snippets, reducing confidence.", "citations": []}
{"abstract_id": 6202, "endpoint_id": 48, "truth": 1, "pred": 1, "blended_prob": 0.8300000000000001, "llm_prob": 0.8, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["no external citation supporting the p\u2011value"], "green": []}, "rationale": "The phase 3 RCT reported a median time to first platelet response of 1.1 weeks for romiplostim versus 2.1 weeks for placebo, with a reported p\u2011value <\u202f0.001, meeting the superiority decision rule (p\u202f<\u202falpha). Sample size (165 patients) and randomized, placebo\u2011controlled design support robustness of this endpoint.", "citations": []}
{"abstract_id": 2329, "endpoint_id": 122, "truth": 0, "pred": 0, "blended_prob": 0.36611764705882355, "llm_prob": 0.12, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation for the PFS p\u2011value; reliance on trial summary rather than retrieved source"], "green": []}, "rationale": "The exploratory analysis reports a log\u2011rank P value of 0.519 for PFS comparison between DDR\u2011mutated and non\u2011mutated patients, which does not meet the p\u202f<\u202f0.05 significance threshold; thus the endpoint is not statistically significant despite the small sample size and single\u2011arm design.", "citations": []}
{"abstract_id": 3719, "endpoint_id": 287, "truth": 1, "pred": 1, "blended_prob": 0.7070000000000001, "llm_prob": 0.72, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited sample size (25 per arm) and lack of external citation for the reported p\u2011value"], "green": []}, "rationale": "The trial reports a 14% vs 10% improvement in emotional well\u2011being with a p\u2011value of 0.045, which meets the predefined significance threshold (p<0.05). However, the small randomized sample (n=50) limits robustness and generalizability.", "citations": []}
{"abstract_id": 4390, "endpoint_id": 230, "truth": 1, "pred": 1, "blended_prob": 0.8194482758620689, "llm_prob": 0.86, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target alk has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["design"]}, "rationale": "The single\u2011arm phase\u202fII trial enrolled 33 patients and observed a major pathological response in 15 of 33 (46%, 90%\u202fCI\u202f31\u201161%). This exceeds the Simon\u2019s two\u2011stage design target of 40% (P1) and is well above the null hypothesis of 20% (P0), indicating the primary endpoint was met.", "citations": [{"title": "ALNEO trial \u2013 neoadjuvant alectinib in stage\u202fIII ALK\u2011positive NSCLC (NCT05015010)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05015010"}]}
{"abstract_id": 2345, "endpoint_id": 124, "truth": 1, "pred": 1, "blended_prob": 0.663448275862069, "llm_prob": 0.6, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the specific ORR result is limited to trial summary; no direct citation from retrieved snippets confirming the numeric outcome."], "green": []}, "rationale": "The trial was designed to require \u226523 objective responses (\u224868% ORR) in a Simon's two\u2011stage design. The reported confirmed ORR of 67.6% in 37 patients exceeds this threshold, indicating the primary endpoint was met, though the supporting evidence is limited to the trial description rather than external citations.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 1618, "endpoint_id": 96, "truth": 1, "pred": 1, "blended_prob": 0.7077777777777778, "llm_prob": 0.55, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target braf has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm DLT outcomes"], "green": []}, "rationale": "The primary endpoint requires identification of a maximum tolerated dose via a 3+3 design assessing dose\u2011limiting toxicities in Cycle\u202f1. The trial report indicates no DLTs were observed, suggesting the MTD was not reached within the tested dose range, which would mean the endpoint is not met. However, this conclusion relies on trial details not present in the retrieved evidence, reducing confidence.", "citations": []}
{"abstract_id": 6278, "endpoint_id": 49, "truth": 1, "pred": 0, "blended_prob": 0.48057142857142854, "llm_prob": 0.42, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["insufficient specific evidence for dyspnea outcome; trial data not present in retrieved sources"], "green": []}, "rationale": "The trial reports a p\u2011value of 0.02 for dyspnea favoring the cannabis extract, which meets the <0.05 superiority rule, but the specific result is not found in the retrieved evidence, limiting confidence.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1292, "endpoint_id": 71, "truth": 1, "pred": 1, "blended_prob": 0.8583999999999999, "llm_prob": 0.96, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["endpoint observed as per protocol"]}, "rationale": "The phase\u20111 single\u2011arm trial of LB1410 reported that no dose\u2011limiting toxicities were observed across all dose cohorts up to 20\u202fmg/kg, directly satisfying the primary decision rule of absence of DLTs. The sample size (79 treated patients) is adequate for a phase\u20111 safety assessment.", "citations": [{"title": "LB1410 dose escalation and expansion study (Keyplus-001)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05357651"}]}
